Zhimeng Biopharma Overview
- Founded
-
2017
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$54.6M
- Investors
-
16
Zhimeng Biopharma General Information
Description
Developer of pharmaceuticals designed to target all stages of the hepatitis B virus. The company has nuclecapsid inhibitor, RNA destabilizer and immunomodulator projects in the pipeline, enabling healthcare professionals to prescribe better treatments to patients.
Contact Information
Website
www.core-biopharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- Suite A-302
- No. 1976 Gaoke Middle Road, China (Shanghai) Pilot Free Trade Zone
- Shanghai, 201210
- China
+86 021 0000 0000
Zhimeng Biopharma Timeline
Zhimeng Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | 08-Nov-2021 | $54.6M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 3. Later Stage VC (Series A) | 06-Nov-2020 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 2. Early Stage VC | 11-Nov-2019 | $14.2M | $14.2M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC | 05-Feb-2018 | Completed | Startup |
Zhimeng Biopharma Patents
Zhimeng Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020333708-A1 | 2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof | Pending | 19-Aug-2019 | 00000000 | |
| CA-3147836-A1 | 2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof | Pending | 19-Aug-2019 | 00000000 | |
| EP-4019517-A1 | 2-aminopyrimidine compounds and pharmaceutical compositions and uses thereof | Pending | 19-Aug-2019 | 0000000000 | |
| AU-2019272383-A1 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | Granted | 22-May-2018 | 0000000000 | |
| CA-3101226-A1 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | Pending | 22-May-2018 | C07D451/00 |
Zhimeng Biopharma Executive Team (3)
Zhimeng Biopharma Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Advantech Capital Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| Co-Stone Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Dawu Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| DYEE Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Fellow Partners | Venture Capital | Minority | 000 0000 | 000000 0 |